CSPC Pharmaceutical Group Ltd
OTC:CSPCY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CSPC Pharmaceutical Group Ltd
OTC:CSPCY
|
CN |
|
R
|
Revance Therapeutics Inc
F:RTI
|
US |
|
Equitable Holdings Inc
F:AXJ
|
US |
|
A
|
Australian Vanadium Ltd
OTC:ATVVF
|
AU |
|
A
|
Arrow Electronics Inc
XMUN:ARW
|
US |
|
M
|
Muenchener Rueckversicherungs Gesellschaft in Muenchen AG
OTC:MURGY
|
DE |
|
O
|
Outcrop Silver & Gold Corp
XMUN:MRG
|
CA |
|
G
|
Gentex Corp
XMUN:GTX
|
US |
Wall St Price Targets
CSPCY Price Targets Summary
CSPC Pharmaceutical Group Ltd
According to Wall Street analysts, the average 1-year price target for CSPCY is 6.07 USD with a low forecast of 3.48 USD and a high forecast of 10.62 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CSPCY's stock price target?
Price Target
6.07
USD
According to Wall Street analysts, the average 1-year price target for CSPCY is 6.07 USD with a low forecast of 3.48 USD and a high forecast of 10.62 USD.
What is the Revenue forecast for CSPC Pharmaceutical Group Ltd?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for CSPC Pharmaceutical Group Ltd?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Operating Income has been 21%. The projected CAGR for the next 8 years is 14%.
What is the Net Income forecast for CSPC Pharmaceutical Group Ltd?
Projected CAGR
18%
Over the last 14 years, the compound annual growth rate for Net Income has been 24%. The projected CAGR for the next 3 years is 18%.
